CHOOSE TREMFYA®, GET TREMFYA®

When you choose TREMFYA®, different patient-support programs may help patients get TREMFYA®, depending on their coverage. Patients with government insurance may not have coverage for TREMFYA®. Learn more about specific patient-support programs and eligibility requirements.

ALSO APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

INDICATIONS

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported. TREMFYA® may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a clinically important or serious infection develops, discontinue TREMFYA® until infection resolves. Evaluate for tuberculosis before treating with TREMFYA®. Avoid use of live vaccines in patients treated with TREMFYA®. Please see related and other Important Safety Information.

Tremfya® (guselkumab)

janssen Immunology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

CHOOSE TREMFYA®, GET TREMFYA®

START WITH TREMFYA® SO SIMPLE TRIAL PROGRAM

The TREMFYA® So Simple Trial Program provides patients their first dose of TREMFYA® so they may determine with their provider if it is right for them.

1. **FORM** for easy enrollment
2. $0 **COST** to patient
3. Shipment can be authorized within **3 BUSINESS DAYS** after prescription.*

This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends.

*Shipment can be authorized within 3 business days of submitting a prescription pending patient program opt-in and scheduling shipment.

SUBMIT A COMPLETED PRESCRIPTION ENROLLMENT FORM

These programs are for medication only. Terms expire at the end of each program year and may change.

FOR COMMERCIALLY INSURED PATIENTS

STAY ON TREMFYA®

SUBMIT A COMPLETED PRIOR AUTHORIZATION FORM

to the patient's insurance company

Click here for Prior Authorization information

INSURANCE COVERAGE APPROVED

JANSSEN CAREPATH SAVINGS PROGRAM

Eligible patients pay $5 per injection

with a $20,000 maximum program benefit per calendar year

See full program requirements at Tremfya.JanssenCarePathSavings.com.

Use the **EXPRESS ENROLLMENT** site at JanssenCarePathPortal.com/express to enroll eligible patients in the Janssen CarePath Savings Program

COVERAGE DELAYED >5 BUSINESS DAYS OR DENIED

Janssen Link

Patients will receive TREMFYA® at no cost until they receive insurance coverage approval

See full program requirements at JanssenCarePath.com/Tremfya/Janssen-Link.

Both programs are unavailable to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration.

Tremfya® (guselkumab)

SUPPORT RESOURCES

Field Reimbursement and Access Specialist (FRAS)

Reimbursement and Access Specialists:

- Educate about TREMFYA® coverage
- Discuss affordability options
- Respond to questions about the exceptions and appeals process

Contact your local Reimbursement and Access Specialist.

BioCoordiNATION™

The one destination for the information and resources you may need to help patients start and stay on TREMFYA®.

TremfyaBioCoordiNATION.com is a source for access, affordability, and treatment support for your patients.

TREMFYA® Injection Training Support Program

Helping Your Patients on Their Self-injection Treatment Journey

- The self-injection training is conducted live by a registered nurse, via virtual video engagements or phone
- The patient can only enroll once they have confirmed that initial self-injection training has been completed in the provider's office and the provider has decided that the patient is ready to self-inject
- This program is intended as patient education to reinforce proper injection technique

Patients can visit TremfyaHCP.com to complete the Injection Training Support Program Enrollment Form to request additional support once they have received self-injection training/instruction from their provider or their provider's staff.

The TREMFYA® Injection Training Support Program is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe. In-person live training may not be available in all areas.

Janssen CarePath | **WE CAN HELP MAKE IT SIMPLE FOR YOU TO HELP YOUR PATIENTS**

Janssen CarePath Is Your One Source for Access, Affordability, and Treatment Support for Your Patients

Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on TREMFYA® that you prescribed.

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday to Friday, 8:00 AM to 8:00 PM ET

Sign Up or Log In to the Provider Portal

Visit JanssenCarePath.com

covermymeds®

Prior Authorization Support* for TREMFYA®

Janssen can provide information and resources on the prior authorization (PA) process to help your patients get started on their prescribed Janssen medication.

CoverMyMeds® is a third-party service provider whose standard process allows for the secure electronic communication of prior authorization information between providers, payers and pharmacies through their online portal.

Janssen has entered into a contract with CoverMyMeds® to allow pharmacies to initiate PA requests to providers upon Rx rejection, and alert the provider that the medication requires a PA. Providers can access this functionality on CoverMyMeds.com or the Janssen CarePath Provider Portal at JanssenCarePathPortal.com.

For information on CoverMyMeds®, call 866-452-5017, Monday to Friday 8 AM to 11 PM ET and Saturday 8 AM to 6 PM ET or visit CoverMyMeds.com.

*CoverMyMeds® does not fill out any information that requires the medical judgment of the prescriber, and only the prescriber can determine whether to submit a prior authorization for a determination.

iAssist® Powered by AssistRx

AssistRx is a third-party technology solutions provider. Janssen Biotech, Inc., has contracted with AssistRx to develop a customized and branded workflow within the iAssist® platform that helps connect patients to the Janssen programs that support them after their treatment is prescribed.

Click here to register with iAssist®.

INDICATIONS

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

Tremfya® (guselkumab)

janssen Immunology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson